KALV KalVista Pharmaceuticals, Inc.companySEC Filings & Insider Trading Activity 2026
Latest KalVista Pharmaceuticals, Inc. (KALV) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on July 10, 2025, a 10-Q quarterly report filed on November 10, 2025, an 8-K current report filed on April 29, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for KalVista Pharmaceuticals, Inc. (KALV) (SEC CIK 1348911), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
Frequently Asked Questions
What are the latest KALV SEC filings in 2026?
KalVista Pharmaceuticals, Inc. (KALV) has filed a 10-K annual report on July 10, 2025, a 10-Q quarterly report on November 10, 2025, an 8-K current report on April 29, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did KALV file its most recent 10-K annual report?
KalVista Pharmaceuticals, Inc. (KALV) filed its most recent 10-K annual report on July 10, 2025. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view KALV 10-Q quarterly reports?
KalVista Pharmaceuticals, Inc. (KALV)'s most recent 10-Q quarterly report was filed on November 10, 2025. SignalX displays every KALV 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has KALV filed recently?
KalVista Pharmaceuticals, Inc. (KALV)'s most recent 8-K was filed on April 29, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find KALV insider trading activity (Form 4)?
SignalX aggregates every KALV Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does KALV file with the SEC?
KalVista Pharmaceuticals, Inc. (KALV) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new KALV filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for KalVista Pharmaceuticals, Inc. (KALV).
What is KALV's SEC CIK number?
KalVista Pharmaceuticals, Inc. (KALV)'s SEC CIK (Central Index Key) number is 1348911. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1348911 to look up all KALV filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find KALV return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from KalVista Pharmaceuticals, Inc. (KALV) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of KalVista Pharmaceuticals, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 46+ filings.